Whalesbook
Hospitals Ka Bada Nuksaan, Patients Ke Liye Mushkil
Dekho, government ki CGHS scheme ne cancer ki مہنگی, patented immunotherapy drugs ke liye payment ka ek naya rule laya hai. Ab woh MRP (Maximum Retail Price) ka sirf 70% de rahe hain. Iska matlab hospitals ko khud bache hue 30% ka nuksaan uthana pad raha hai. Yeh unke liye sambhalna bahut difficult ho raha hai, kyunki in specialized treatments par profit margin pehle se hi bahut kam, kabhi kabhi sirf 10-15% rehta hai. Association of Healthcare Providers (India) (AHPI) ne toh health ministry ko is crisis ke baare mein warning bhi de di hai. Unhone bataya ki 9 khaas patented immunotherapy drugs ab CGHS beneficiaries ke liye milna lagbhag impossible ho raha hai.
Price Ka Chakravyuh: Dawaaiyan Mehngi, Paise Kam
Asal problem yeh hai ki ye patented immunotherapy drugs itni mehengi hain aur government ka payment limit bahut kam. Example ke liye, 'Keytruda' jaise ek important immunotherapy drug ka cost India mein lagbhag ₹1.5 lakh per 100 mg vial hai. Aur monthly treatment ka kharcha ₹3 lakh se bhi zyada ho sakta hai! CGHS policy ke hisab se, hospitals ko MRP ka sirf 70% milta hai, jisse unki jeb se baaki 30% amount jaata hai. Advanced cancer treatments ke liye yeh bahut bada financial burden hai. Indian oncology drug market toh badh raha hai, par payment systems ki yeh problem access ko rok rahi hai.
Operational Issues Aur Badi Pareshaniyan
Hospitals ko is policy mein practical aur legal issues aa rahe hain. Ek toh yeh ki hospitals CGHS ko full MRP par bill karte hain, par unhein milta sirf 70% hai, jo seedha unke profit ko kam karta hai. Kai hospitals multinational pharma companies se bulk mein drugs kharidne ke liye complex contracts karte hain, jismein unhein negotiated price disclose karne ki permission nahi hoti. Agar woh CGHS ko purchase invoice dikhayenge toh contract break hone ka risk hai. Dusra option patients ko bolna hai ki woh khud dawaai kharid lein, par yeh medically risky hai. In dawaaiyon ko strict temperature control chahiye hota hai, aur patients ke liye asli aur sahi stored drugs ensure karna mushkil hai. Iske alawa, CGHS ki apni supply chain mein bhi pehle delays aur shortages dekhi gayi hain.
Private Providers Par Financial Pressure
Government health schemes, jaise CGHS, bade private hospital networks ke revenue ka kaafi bada hissa hoti hain, estimate 20-25% tak. Lekin ab yeh share pressure mein hai. Analysts predict kar rahe hain ki FY27 ki pehli quarter tak revenue aur 3-5% gir sakta hai, kyunki hospitals isme involvement kam kar rahe hain ya beds kam kar rahe hain. Max Healthcare ne bataya ki CGHS se unko ₹200 crore ka revenue impact hua hai. Iska asar hospitals ki market value par bhi dikh raha hai. Max Healthcare ka market cap lagbhag ₹98,871 crore hai aur Apollo Hospitals ka ₹111,253 crore. Fortis Healthcare (₹71,687 crore) aur HealthCare Global Enterprises (HCG) (₹8,612 crore) jaise kuch stocks ke high P/E ratios bhi investor caution dikha rahe hain.
Policy Ka Rukna Aur Changes
CGHS reimbursement rates pehle se hi ek recurring issue rahe hain. October 2025 mein ek major update se pehle, kai procedures ke rates 2014 se change nahi hue the. October 2025 mein jo revision hua, usme ek tiered, quality-linked pricing structure laya gaya, jismein reimbursement ko hospital accreditation, city tier, aur ward entitlement se joda gaya. Is reform ka aim financial viability aur accessibility improve karna tha. Lekin cancer drugs par 70% MRP cap ka issue abhi bhi ek bada obstacle bana hua hai. AHPI consistently full MRP payment ki demand kar raha hai essential medicines ke liye.
Provider Challenges Aur Risks
Hospitals ko hamesha government reimbursement schemes mein kaam karne mein difficulties aati hain. Max Healthcare, Fortis Healthcare, aur HealthCare Global Enterprises jaise bade hospital groups ne publicly kaha hai ki unko CGHS jaisi schemes se kafi revenue loss aur financial difficulties hui hain. AHPI ne pehle ₹500 crore se zyada ka overdue payment bhi pointed out kiya tha jo 60 se zyada private hospitals ko milna tha, aur reimbursement delays bhi lambe the.
Policy environment ki wajah se private providers ke liye yeh situation weak hai. Private insurance ya self-pay patients se zyada profit milta hai. Lekin CGHS ka life-saving patented drugs ke liye reimbursement cap hospitals ko ek difficult financial spot par rakh raha hai, jisse ho sakta hai woh yeh advanced treatments offer karne se katrein. Indian oncology market badh raha hai, par cancer treatments ke liye sufficient payment plans ki kami access mein ek major barrier hai.
Sabse bada risk yeh hai ki cost aur payment shortfalls ki wajah se patients ko essential, life-saving immunotherapy drugs milne mein bahut limited access ho jaye. Hospitals contract break hone ka risk le rahe hain drug makers ke saath agar woh rules ke against prices disclose karte hain. Isse crucial medicines ki supply mein disruption aa sakti hai. Financial pressure ki wajah se hospitals ki long-term stability aur new technology mein investment bhi affect ho sakta hai, jisse overall healthcare quality par bhi asar padega. Yeh policy situation advanced cancer treatments tak access expand karne ke aim ko undermine kar sakti hai.
Association of Healthcare Providers (India) (AHPI) ab CGHS se demand kar raha hai ki woh apni payment policy review kare aur critical patented oncology drugs ke liye full MRP payment dein. Isse hospitals ki financial sustainability bani rahegi aur patients ko access milta rahega. Indian oncology market toh growth ke liye ready hai, lekin ye treatments kitne effective honge yeh government ki payment policies par depend karega, jo advanced, life-saving medications ke real costs ko match karein.